U.S. Orthopedics Makers Shift Production To China
This article was originally published in PharmAsia News
Executive Summary
U.S. production of medical devices, long considered unlikely to join the outsourcing move to Southeast Asia, now is migrating to China as firms see it as a good place to make wares. Two orthopedic companies in Indiana already have opened plants in the country and a third has one under construction. The three are Biomet, DePuy Orthopaedics and Paragon Medical. The shift is not just for devices sold in Asia; it also includes production of products for the U.S. market. (Click here for more
You may also be interested in...
China Still Alluring? AZ, Pfizer Feel COVID Pinch, New Pricing Scheme Clouds Outlook
Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.
Coronavirus Update: BioNTech And Fosun Launch Vaccine Trial In China
The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.
QUOTED. 6 August 2020. Department of Health and Social Care.
The UK Department of Health and Social Care recently asked medical device and pharmaceutical companies to establish contingency measures in case of supply problems post-Brexit.
Need a specific report? 1000+ reports available
Buy Reports